Anatumomab mafenatox

Anatumomab mafenatox
Monoclonal antibody
Type Fab fragment
Source Mouse
Target TAG-72
Clinical data
ATC code none
CAS Number 1370261-50-9
ChemSpider none

Anatumomab mafenatox is a mouse monoclonal antibody for the treatment non-small cell lung cancer,[1] which acts as a tumor-targeted superantigen.[2]

It is a fusion protein of a human tumor-associated glycoprotein 72-specific monoclonal IgG1 Fab fragment with an enterotoxin ('mafenatox') of Staphylococcus aureus.[3]


  1. "Active Biotech". Retrieved 25 May 2016.
  2. Hedlund, Gunnar; Forsberg, Göran; Nederman, Thore; Sundstedt, Anette; Dahlberg, Leif; Tiensuu, Mikael; Nilsson, Mats (2013). "Tumor-Targeted Superantigens": 365–381. doi:10.1002/9781118354599.ch24.
  3. "Drug info" (PDF). World Health Organisation. Retrieved 25 May 2016.

This article is issued from Wikipedia - version of the 10/22/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.